Clinical Trial Update: Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating venetoclax in combination with the CACAG regimen for relapsed/refractory acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Relapsed/Refractory Acute Myeloid Leukemia | Phase 2 | Status: RECRUITING